Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AGEN1571 |
Synonyms | |
Therapy Description |
AGEN1571 is a human monoclonal antibody that targets ILT2, potentially leading to increased pro-inflammatory cytokine secretion, immune cell activation, and enhanced antitumor immune response (Cancer Res 2022;82(12_Suppl):Abstract nr 2906). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AGEN1571 | AGEN 1571|AGEN-1571 | AGEN1571 is a human monoclonal antibody that targets ILT2, potentially leading to increased pro-inflammatory cytokine secretion, immune cell activation, and enhanced antitumor immune response (Cancer Res 2022;82(12_Suppl):Abstract nr 2906). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05377528 | Phase I | AGEN1571 + Balstilimab + Botensilimab AGEN1571 + Botensilimab AGEN1571 + Balstilimab AGEN1571 | Study of AGEN1571 in Participants With Advanced Solid Tumors | Active, not recruiting | USA | 0 |